Abstract:ABSTRACT The induction of systemic antibody titers against hemagglutinin has long been the main focus of influenza vaccination strategies, but mucosal immunity has also been shown to play a key role in the protection against respiratory viruses. By vaccinating and challenging healthy volunteers, we demonstrated that inactivated influenza vaccine (IIV) modestly reduced the rate of influenza while predominantly boosting serum antibody titers against hemagglutinin (HA) and HA stalk, a consequence of the low neuraminidase (NA) content of IIV and the intramuscular route of administration. The viral challenge induced nasal and serum responses against both HA and NA. Correlations between mucosal IgA and serum IgG against specific antigens were low, whether before or after challenge, suggesting a compartmentalization of immune responses. Even so, volunteers who developed viral shedding for multiple days had lower baseline titers across both systemic and mucosal compartments as compared to those with no shedding or a single day of shedding. Regression analysis showed that pre-challenge HA inhibition titers were the most consistent correlate of protection across clinical outcomes combining shedding and symptoms, with NA inhibition titers and HA IgG levels only predicting the duration of shedding. Despite the inclusion of data from multiple binding and functional antibody assays against HA and NA performed on both serum and nasal samples, multivariate models were unable to account for the variability in outcomes, emphasizing our imperfect understanding of immune correlates in influenza and the importance of refining models with assessments of innate and cellular immune responses. IMPORTANCE The devastating potential of influenza has been well known for over 100 years. Despite the development of vaccines since the middle of the 20th century, influenza continues to be responsible for substantial global morbidity and mortality. To develop next-generation vaccines with enhanced effectiveness, we must synthesize our understanding of the complex immune mechanisms culminating in protection. Our study outlines the differences in immune responses to influenza vaccine and influenza infection, identifying potential gaps in vaccine-induced immunity, particularly at the level of the nasal mucosa. Furthermore, this research underscores the need to refine our imperfect models while recognizing potential pitfalls in past and future attempts to identify and measure correlates of protection.

Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface

A Broadly Protective Therapeutic Antibody Against Influenza B Virus with Two Mechanisms of Action

Broadly protective human antibodies that target the active site of influenza virus neuraminidase

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.

Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase

Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin

Two Escape Mechanisms of Influenza A Virus to A Broadly Neutralizing Stalk-Binding Antibody

Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses

A pan-influenza antibody inhibiting neuraminidase via receptor mimicry

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

Influenza Neuraminidase Characteristics and Potential as a Vaccine Target

Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability

Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies

A new class of antibodies that overcomes a steric barrier to cross-group neutralization of influenza viruses

CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age

Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers

Broadly neutralizing antibodies recognizing different antigenic epitopes act synergistically against the influenza B virus.

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface

Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies